Image courtesy of hywards at FreeDigitalPhotos.net
Have you recently been recommended to take BIOLOGIC medications for Rheumatoid Arthritis?
The latest online tool to help make your treatment decisions.
We are looking for people with rheumatoid arthritis to test a new online tool that helps to make decisions about using biologic medications.
If you have been recommended to consider using a biologic by your doctor but have not started yet, we invite you to participate in this study.
You may be eligible if you:
- Have rheumatoid arthritis
- See a rheumatologist
- Have received a recommendation to consider biologic therapy
- Have a valid email and internet access
The study will take about two hours to complete over a span of four to six weeks, and can be completed remotely. Any information you provide will be completely confidential. An honorarium will be provided for your time.
If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email firstname.lastname@example.org.
The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey confirms psoriasis and psoriatic arthritis (PsA) are frequently under treated or not treated at all. MAPP is the first probability survey that looked at patients, regardless of whether they were under the care of a healthcare provider or member of a patient advocacy group, and also included the physician perspective. The survey interviewed 3,426 patients who were randomly selected via a telephone survey of 139,948 households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom. It also interviewed a total of 781 physicians from North America and Europe. The survey explored the following: Continue reading
Cheryl Koehn, President of Arthritis Consumer Experts (ACE), spoke in today’s session at the 2014 CADTH Symposium held at the Hilton Lac-Leamy, Gaitneu, Quebec. The 2014 CADTH Symposium is the tenth pan-Canadian forum organized by the Canadian Agency for Drugs and Technologies in Health for producers and users of evidenced-based information on drugs and other health technologies in Canada. This year's Symposium is titled The Realities of Health Care Decision-Making: Evidence, Values, and Collaboration and comprises of 3 plenary sessions, 22 panel discussions, 9 oral sessions, 13 workshops and more than 40 scientific posters - all helping to enhance decision-making, reduce uncertainty, improve health outcomes and increase the value and sustainability of health care in Canada and around the world.
ACE is proud to be a part of the Symposium. Cheryl was one of the panellists today at "Session D2 - Panel Discussion: Health Technology Assessment of Biosimiliars (Subsequent Entry Biologics): A Canadian Perspective." She spoke alongside the following panellists: Continue reading